DVA's Quality Score fell 1 point on Mon, Nov 2, to 10.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Up 145% over three years while the S&P 500 rose 89%.
| The chart | Above every average |
| Latest filing | 8-K, Oct 29 |
After its last 4 reports it closed +6.1% on average, higher 2 of 4 times.
Averagefor quality, not price, 4 of 14 chart checks firingWhat the Quality Score means
DVA is #2 of 5 by Quality Score among Services-Miscellaneous Health & Allied Services.
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score |
Expected to report Mon Feb 1, after the close (in 91 days). Expected.
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
Sales of $3.6B, 5% more than a year ago; a profit of $3.40 a share, from $2.04.
DVA's results filing gives no sales by line in a table we read.
No outlook figures read from this release.
Sales grew 3.4% a year over 5 years, fiscal 2020 to 2025.
Its share count fell 9.2% a year over 5 years.
| Reported | Gap | Reaction | 5 sessions |
|---|---|---|---|
| Oct 29, 2026 | -9.5% | -3.0% | open |
| Aug 4, 2026 | -10.0% | -17.2% | -21.8% |
| May 5, 2026 | +7.8% | +23.5% | +27.7% |
Sales grew in five of the last seven years, to $14B in 2025. It made a profit in each of the eight years.
6 insiders sold $141M across 11 filings in the last 6 months. No open-market buys on record. The newest:
One trade disclosed in the last six months. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: DVA is under 0.1% of IVV, under 0.1% of SPY, and under 0.1% of VOO, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026 (SPY's as filed by IVV).
DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.
“The U.S. dialysis industry remains highly competitive and is continuously evolving.”
DVA scores 10 today, which Breakaway calls Average. It is #2 of 5 in Services-Miscellaneous Health & Allied Services by Quality Score, with 4 of 14 chart checks firing. Up 145% over three years while the S&P 500 rose 89%. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
DVA scores 10 today, which Breakaway calls Average (6 to 10). That is #2 of 5 in Services-Miscellaneous Health & Allied Services by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind DVA's 10.
6 insiders sold $141M across 11 filings in the last 6 months. No open-market buys on record. The newest is Berkshire Hathaway Inc, 10% owner, who sold $69M on Oct 27. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.